Carisma Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Carisma Therapeutics

11/05/2023 14:54

* Carisma Therapeutics Inc  CARM.OQ  reported a quarterly
adjusted
loss of $1.93​​ per share for the quarter ended in March. The
lone analyst forecast for the quarter was for a loss of 89 cents
per share.
    * Revenue was $3.24 million​; analysts expected $3.73
million. 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Carisma Therapeutics Inc shares had risen by 89.0% this
quarter and gained 13.1% so far this year.
    * Wall Street's median 12-month price target for Carisma
Therapeutics Inc is $11.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 01:54 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.89          -1.93          Missed
 Dec. 31 2022      -2.20          -0.80          Beat
 Sep. 30 2022      -1.60          2.00           Beat
 Jun. 30 2022      -2.60          -3.20          Missed